Strike early-strike strong lipid-lowering strategy with PCSK9i in ACS patients. Real-world evidence from AT-TARGET-IT registry.
Paola GargiuloChristian BasileGennaro GalassoMichele BellinoDebora D'EliaGiuseppe PattiManuel BoscoMatteo PrinettiGiuseppe AndòFrancesca CampanellaGiovanni TavernaPaolo CalabròArturo CesaroFabio FimianiAngelo CatalanoFerdinando VarbellaAntonella CorletoFrancesco BarillàSaverio MuscoliGiuseppe MusumeciFabrizio DelnevoFrancesco GiallauriaRaffaele NapoliItalo PortoAlberto PolimeniRossella QuartaAlessandro MalobertiPiera Angelica MerliniLeonardo De LucaGavino CasuNatale Daniele BrunettiMario CrisciLeonardo PalosciaClaudio BilatoCiro IndolfiFederica MarzanoSara FontanarosaDavide BuonocoreAntonio Luca Maria ParlatiErmanno NardiMaria PrastaroAndrea SoricelliMarco SalvatoreStefania PaolilloPasquale Perrone-Filardinull nullPublished in: European journal of preventive cardiology (2024)
Intensive and early lipid-lowering therapy using PCSK9i in patients with ACS (strike early strike strong strategy) is safe and effective in clinical practice and associated with a reduction of residual CV risk.